Why the study?
The coexistence of HFpEF and MASLD presents significant clinical challenges due to shared metabolic pathophysiology and complex interplay, making management strategies challenging.
SGLT2 inhibitors and GLP-1 receptor agonists represent promising metabolic solutions for the complex clinical challenge of coexisting HFpEF and MASLD.
Heart failure (HF) with preserved ejection fraction (HFpEF) has exceeded HF with reduced ejection fraction (HFrEF), becoming the most common type of HF. Unlike HFrEF, HFpEF is primarily a chronic low-grade inflammatory process closely associated with metabolic disorders. The coexistence of HFpEF and metabolic dysfunction-associated steatotic liver disease (MASLD) presents significant clinical challenges due to shared metabolic pathophysiology and complex interplay. Management strategies for HFpEF and MASLD remain challenging. Sodium-glucose cotransporter 2 inhibitors have shown benefits in managing both conditions. Additionally, glucagon-like peptide-1 receptor agonists are being actively investigated for their potential benefits, particularly in MASLD. A comprehensive, patient-centered approach that combines metabolic and cardiovascular care is essential for improving outcomes in patients with HFpEF and MASLD, addressing the global metabolic health challenges.
No takes yet. Share an insight, caveat, or question.
Lian et al. (2025) conducted a letter in Heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatotic liver disease (MASLD). Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: